Today, AstraZeneca announced a major $820 million investment in Canada, creating over 700 high-skilled jobs and moving to a new, state-of-the-art office within Mississauga. This investment supports AstraZeneca’s ambitious goal of reaching US$80 billion in total revenue by 2030, with plans to deliver 20 new medicines globally.
As one of Canada’s leading R&D investors, AstraZeneca’s contributions exceeded C$1.3 billion since 2023, supporting over 210 global clinical studies. The company’s recent acquisition of Fusion Pharmaceuticals, a pioneer in next-gen cancer therapies, further strengthens its commitment to innovation and advancing the life sciences sector in Canada.
This investment highlights the growth of Canada’s life sciences ecosystem and solidifies AstraZeneca’s role in driving global healthcare innovation. The team at Invest Mississauga looks forward to further supporting AstraZeneca with their exciting growth plans!
Read the full press release here.